Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis of Recurrence and Progression.

NCT03982797 is registered in ClinicalTrials.gov with Biofabri, S.L as lead sponsor.

NCT NCT03982797
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03982797 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis of Recurrence and Progression.
Lead sponsor
Biofabri, S.L
Phase
Phase 2
Overall status
Unknown status
Start date
May 17, 2019
Completion date
March 3, 2022
Enrollment
306 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer